Loading...

We've got a brand new version of Simply Wall St! Try it out

ASLAN Pharmaceuticals

GTSM:6497
Snowflake Description

Slightly overvalued with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6497
GTSM
NT$2B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

ASLAN Pharmaceuticals Limited operates as a clinical-stage oncology and inflammatory disease focused biopharmaceutical company in the United States. The last earnings update was 11 days ago. More info.


Add to Portfolio Compare Print
  • ASLAN Pharmaceuticals has significant price volatility in the past 3 months.
6497 Share Price and Events
7 Day Returns
6.9%
GTSM:6497
-1%
TW Biotechs
1.4%
TW Market
1 Year Returns
-69.5%
GTSM:6497
-9.6%
TW Biotechs
17.7%
TW Market
6497 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ASLAN Pharmaceuticals (6497) 6.9% -0.1% -42.5% -69.5% - -
TW Biotechs -1% -2.6% -4.5% -9.6% -39.9% -41.4%
TW Market 1.4% 6% 9.8% 17.7% 27.6% 27.7%
1 Year Return vs Industry and Market
  • 6497 underperformed the Biotechs industry which returned -9.6% over the past year.
  • 6497 underperformed the Market in Taiwan, Province of China which returned 17.7% over the past year.
Price Volatility
6497
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for ASLAN Pharmaceuticals's competitors could be found in our database.

6497 Value

 Is ASLAN Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of ASLAN Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for ASLAN Pharmaceuticals.

GTSM:6497 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 11%
Perpetual Growth Rate 10-Year TW Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for GTSM:6497
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year TW Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.28
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.278 (1 + (1- 17%) (28.69%))
1.39
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.39
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.39 * 5.96%)
11.02%

Discounted Cash Flow Calculation for GTSM:6497 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for ASLAN Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

GTSM:6497 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 11.02%)
2020 -28.25 Analyst x1 -25.45
2021 -13.38 Analyst x1 -10.85
2022 2.70 Analyst x1 1.97
2023 31.05 Analyst x1 20.44
2024 53.69 Est @ 72.93% 31.84
2025 81.54 Est @ 51.87% 43.56
2026 111.82 Est @ 37.13% 53.80
2027 141.79 Est @ 26.81% 61.45
2028 169.56 Est @ 19.58% 66.19
2029 194.19 Est @ 14.53% 68.29
Present value of next 10 years cash flows $311.00
GTSM:6497 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $194.19 × (1 + 2.73%) ÷ (11.02% – 2.73%)
$2,407.33
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,407.33 ÷ (1 + 11.02%)10
$846.54
GTSM:6497 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $311.00 + $846.54
$1,157.54
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,157.54 / 160.49
$7.21
GTSM:6497 Discount to Share Price
Calculation Result
Exchange Rate USD/TWD
(Reporting currency to currency of GTSM:6497)
30.4
Value per Share
(TWD)
= Value per Share in USD x Exchange Rate (USD/TWD)
= $7.21 x 30.4
NT$219.26
Value per share (TWD) From above. NT$219.26
Current discount Discount to share price of NT$9.89
= -1 x (NT$9.89 - NT$219.26) / NT$219.26
95.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price ASLAN Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is NT$9.89 vs Future cash flow value of NT$219.26
Current Discount Checks
For ASLAN Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • ASLAN Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • ASLAN Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ASLAN Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ASLAN Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:6497 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-0.17
GTSM:6497 Share Price ** GTSM (2019-11-08) in TWD NT$9.89
GTSM:6497 Share Price converted to USD reporting currency Exchange rate (TWD/ USD) 0.033 $0.33
Taiwan, Province of China Biotechs Industry PE Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 41.22x
Taiwan, Province of China Market PE Ratio Median Figure of 1,438 Publicly-Listed Companies 16.62x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ASLAN Pharmaceuticals.

GTSM:6497 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:6497 Share Price ÷ EPS (both in USD)

= 0.33 ÷ -0.17

-1.91x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ASLAN Pharmaceuticals is loss making, we can't compare its value to the TW Biotechs industry average.
  • ASLAN Pharmaceuticals is loss making, we can't compare the value of its earnings to the Taiwan, Province of China market.
Price based on expected Growth
Does ASLAN Pharmaceuticals's expected growth come at a high price?
Raw Data
GTSM:6497 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.91x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-18.6%per year
Asia Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.61x
Taiwan, Province of China Market PEG Ratio Median Figure of 244 Publicly-Listed Companies 1.14x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ASLAN Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ASLAN Pharmaceuticals's assets?
Raw Data
GTSM:6497 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $0.08
GTSM:6497 Share Price * GTSM (2019-11-08) in TWD NT$9.89
GTSM:6497 Share Price converted to USD reporting currency Exchange rate (TWD/ USD) 0.033 $0.33
Taiwan, Province of China Biotechs Industry PB Ratio Median Figure of 40 Publicly-Listed Biotechs Companies 3.4x
Taiwan, Province of China Market PB Ratio Median Figure of 1,939 Publicly-Listed Companies 1.46x
GTSM:6497 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:6497 Share Price ÷ Book Value per Share (both in USD)

= 0.33 ÷ 0.08

3.95x

* Primary Listing of ASLAN Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ASLAN Pharmaceuticals is overvalued based on assets compared to the TW Biotechs industry average.
X
Value checks
We assess ASLAN Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ASLAN Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

6497 Future Performance

 How is ASLAN Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-18.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ASLAN Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare ASLAN Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare ASLAN Pharmaceuticals's earnings growth to the Taiwan, Province of China market average as it is expected to be loss making during the next 1-3 years.
  • ASLAN Pharmaceuticals's revenue growth is expected to exceed the Taiwan, Province of China market average.
Annual Growth Rates Comparison
Raw Data
GTSM:6497 Future Growth Rates Data Sources
Data Point Source Value (per year)
GTSM:6497 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -18.6%
GTSM:6497 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 81%
Taiwan, Province of China Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 65.2%
Taiwan, Province of China Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 60.6%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.3%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 7.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:6497 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:6497 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 31
2022-12-31 3
2021-12-31 18 -13 1
2020-12-31 9 -26 -31 4
2019-12-31 3 -19 -23 4
GTSM:6497 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 3 -29 -27
2019-06-30 3 -33 -34
2019-03-31 3 -36 -37
2018-12-31 -39 -42
2018-09-30 -40 -45
2018-06-30 -38 -41
2018-03-31 -40 -42
2017-12-31 -35 -41
2017-09-30 1 -30 -33
2017-06-30 12 -14 -19
2017-03-31 12 -8 -14
2016-12-31 12 -6 -9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ASLAN Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • ASLAN Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:6497 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from ASLAN Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6497 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 -0.16 -0.16 -0.16 1.00
2019-12-31 -0.14 -0.14 -0.14 1.00
GTSM:6497 Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -0.17
2019-06-30 -0.21
2019-03-31 -0.24
2018-12-31 -0.28
2018-09-30 -0.32
2018-06-30 -0.31
2018-03-31 -0.33
2017-12-31 -0.33
2017-09-30 -0.21
2017-06-30 -0.16
2017-03-31 -0.12
2016-12-31 -0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ASLAN Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess ASLAN Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ASLAN Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

6497 Past Performance

  How has ASLAN Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ASLAN Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ASLAN Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ASLAN Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ASLAN Pharmaceuticals's 1-year growth to the TW Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ASLAN Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ASLAN Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6497 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 3.00 -27.37 6.83 22.12
2019-06-30 2.98 -34.38 8.75 27.35
2019-03-31 2.99 -37.24 9.86 30.20
2018-12-31 -41.52 10.35 31.33
2018-09-30 -45.33 11.27 34.22
2018-06-30 -41.48 10.59 30.75
2018-03-31 -41.74 9.85 31.10
2017-12-31 -40.73 8.94 31.02
2017-09-30 1.34 -32.69 8.58 25.08
2017-06-30 12.00 -19.27 8.33 22.43
2017-03-31 12.26 -13.63 7.81 17.86
2016-12-31 11.51 -9.02 6.93 13.12
2016-09-30 10.61 -6.53 7.67 8.07
2016-06-30 0.25 -15.30 7.39 7.21
2016-03-31 -15.00 7.33 6.67
2015-12-31 -13.67 6.78 6.38
2014-12-31 -14.71 5.63 8.99

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ASLAN Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ASLAN Pharmaceuticals has efficiently used its assets last year compared to the TW Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ASLAN Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ASLAN Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ASLAN Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

6497 Health

 How is ASLAN Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ASLAN Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ASLAN Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ASLAN Pharmaceuticals's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of ASLAN Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ASLAN Pharmaceuticals Company Filings, last reported 1 month ago.

GTSM:6497 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 13.19 14.16 7.99
2019-06-30 18.40 14.26 15.04
2019-03-31 26.27 14.13 21.61
2018-12-31 30.57 13.95 28.87
2018-09-30 41.72 9.78 34.76
2018-06-30 52.87 9.72 44.96
2018-03-31 26.92 9.97 28.51
2017-12-31 35.50 9.68 50.56
2017-09-30 49.89 9.18 60.71
2017-06-30 57.75 8.95 69.71
2017-03-31 33.57 8.70 45.70
2016-12-31 41.51 8.32 51.65
2016-09-30 48.31 8.76 57.64
2016-06-30 43.16 9.00 38.78
2016-03-31 -38.47 64.30 27.68
2015-12-31 -37.50 62.68 26.98
2014-12-31 -25.33 29.52 5.57
  • ASLAN Pharmaceuticals's level of debt (107.4%) compared to net worth is high (greater than 40%).
  • Unable to establish if ASLAN Pharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ASLAN Pharmaceuticals has less than a year of cash runway based on current free cash flow.
  • ASLAN Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 41.8% each year.
X
Financial health checks
We assess ASLAN Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ASLAN Pharmaceuticals has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

6497 Dividends

 What is ASLAN Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ASLAN Pharmaceuticals dividends.
If you bought NT$2,000 of ASLAN Pharmaceuticals shares you are expected to receive NT$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ASLAN Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ASLAN Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:6497 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.8%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1337 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

GTSM:6497 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ASLAN Pharmaceuticals has not reported any payouts.
  • Unable to verify if ASLAN Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ASLAN Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ASLAN Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ASLAN Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ASLAN Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ASLAN Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

6497 Management

 What is the CEO of ASLAN Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Carl Alan Jason Firth
COMPENSATION $0
AGE 46
TENURE AS CEO 8.8 years
CEO Bio

Dr. Carl Alan Jason Morton Firth, EMBA, Ph.D., serves as Chief Executive Officer, President and Director of ASLAN Pharmaceuticals Limited. Dr. Firth is the Founder of ASLAN Pharmaceuticals Pte. Ltd. He serves as an Executive Director at ASLAN Pharmaceuticals Limited. He served as the Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies across the region and advising on M&A transactions. Prior to joining the banking industry, he worked in China and Asia for 4 years leading business development, strategic projects and the development of new products. Prior to joining the banking industry, he worked for AstraZeneca for 10 years in various commercial and R&D roles, including Regional Business Development Director, Asia Pacific and Director of New Product Development, China. He served positions in other commercial areas in the UK, including acquisitions, licensing and competitive intelligence and has over 5 years of pharmaceutical R&D experience. He serves as a Director of Exploit Technologies Pte Ltd. He served as an Independent Non-Executive Director of Uni-Bio Science Group Limited. from April 1, 2014 to November 15, 2017. He is an Adjunct Professor at Duke-NUS Medical School. He serves as Director of ASLAN Singapore, Australia and HK. He serves as the Chairman of ASLAN Taiwan. He serves as Director of Singapore’s Exploit Technologies Pte Ltd and Singapore’s Hummingbird Biosciences. He serves as Director of Kimba Capital Limited and Liberty Park Music Pte Ltd. Dr. Firth holds PhD in Molecular Biology, Master of Arts and Bachelor of Arts in Natural Science from Trinity College, Cambridge University and also holds Executive MBA from London Business School.

CEO Compensation
  • Insufficient data for Carl Alan Jason to compare compensation growth.
  • Insufficient data for Carl Alan Jason to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Management Team Tenure

Average tenure and age of the ASLAN Pharmaceuticals management team in years:

2.4
Average Tenure
46
Average Age
  • The tenure for the ASLAN Pharmaceuticals management team is about average.
Management Team

Carl Alan Jason Firth

TITLE
CEO, President & Executive Director
AGE
46
TENURE
8.8 yrs

Kiran Asarpota

TITLE
Vice President of Finance
AGE
40

Ben Goodger

TITLE
General Counsel
AGE
56
TENURE
3 yrs

Mark McHale

TITLE
Chief Development Officer and Head of R&D
AGE
54
TENURE
0.8 yrs

Charlie Hsu

TITLE
Investor Relations Director

Chi-Chin Wang

TITLE
IR & Corporate Development Director

Stephen Doyle

TITLE
Chief Business Officer
AGE
46
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure and age of the ASLAN Pharmaceuticals board of directors in years:

3.6
Average Tenure
56
Average Age
  • The tenure for the ASLAN Pharmaceuticals board of directors is about average.
Board of Directors

Andrew Howden

TITLE
Independent Chairman
COMPENSATION
$30K
AGE
59
TENURE
0.3 yrs

Carl Alan Jason Firth

TITLE
CEO, President & Executive Director
AGE
46
TENURE
9.3 yrs

Kelvin Sun

TITLE
Independent Non-Executive Director
COMPENSATION
$30K
AGE
56
TENURE
3.6 yrs

David Lane

TITLE
Chairman of Scientific Advisory Board
AGE
66

Jun Wu

TITLE
Non-Executive Director
AGE
52
TENURE
3.6 yrs

Damien Lim

TITLE
Non-Executive Director
AGE
56
TENURE
3.6 yrs

Patrick Tan

TITLE
Member of Scientific Advisory Board

Wei Peng Yong

TITLE
Member of Scientific Advisory Board

Matthew Ng

TITLE
Member of Scientific Advisory Board

Robert Hoffman

TITLE
Independent Non-Executive Director
COMPENSATION
$13K
AGE
53
TENURE
1.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess ASLAN Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ASLAN Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

6497 News

Simply Wall St News

6497 Company Info

Description

ASLAN Pharmaceuticals Limited operates as a clinical-stage oncology and inflammatory disease focused biopharmaceutical company in the United States. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company’s lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor (HER), inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4, as well as gastric cancer. Its Varlitinib is currently being studied in a pivotal clinical trial for biliary tract cancer. In addition, the company is developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase II clinical trials to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. Further, it develops ASLAN005, an antibody that is in preclinical development targeting recepteur d’origine nantais, an immune checkpoint inhibitor. The company has rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. ASLAN Pharmaceuticals Limited has licensing agreement with Array BioPharma, Bristol-Myers Squibb, Almirall, CSL Limited, Hyundai Pharm Co., Ltd., Exploit Technologies Pte Ltd., and BioGenetics Co. Ltd.; and licensing and research collaboration agreement with Nanyang Technological University. The company was founded in 2010 and is headquartered in Singapore.

Details
Name: ASLAN Pharmaceuticals Limited
6497
Exchange: GTSM
Founded: 2010
NT$1,587,235,616
160,488,940
Website: http://aslanpharma.com
Address: ASLAN Pharmaceuticals Limited
83 Clemenceau Avenue,
No. 12-03 UE Square,
Singapore,
239920,
Singapore
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 6497 Ordinary Shares Taipei Exchange TW TWD 01. Jun 2017
NasdaqGM ASLN ADS Nasdaq Global Market US USD 04. May 2018
Number of employees
Current staff
Staff numbers
0
ASLAN Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/11 15:31
End of day share price update: 2019/11/08 00:00
Last estimates confirmation: 2019/11/01
Last earnings filing: 2019/10/31
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.